Nodular Goiter Clinical Trial
Official title:
The Effect of 0.1 mg Recombinant Human Thyrotropin (rhTSH) on Thyroid Radioiodine-uptake and the Degree of Goiter Reduction Following 131I-therapy, in Patients With Benign Non-toxic Nodular Goiter. A Randomized, Double-blind, Placebo-controlled Trial.
Verified date | December 2013 |
Source | Odense University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Denmark: National Board of Health |
Study type | Interventional |
The study aims at clarifying (in a randomized, double-blinded design):
1. Whether stimulation with 0.1 mg rhTSH 24, 48 or 72 hours before induction of a
131I-tracer dosis increases the 131I uptake in patients with atoxic multinodular goitre
and to study which time interval is the most optimal (Part I)
2. Whether patients suffering from atoxic multinodular goitre obtains a corresponding
goitre reduction compared with a control group when stimulating with 0.1 mg rh TSH 24,
48 or 72 hours before 131I therapy and when reducing the thyroid radiation dose to 50
Gy (Part II)
The two studies will be carried out successively on the same patient population. The 131I
uptake will be carried out first followed by the I therapy itself. The patients are compared
with a placebo-treated control group going through the same course of treatment, but the
131I dosis will be 100 Gy (standard treatment). After the 131I therapy, all patients are
followed during one year with a regular ultrasound scan of the thyroid gland and control of
the metabolic status. The patient satisfaction is monitored by the use of a
visual-analogue-scale.
Status | Completed |
Enrollment | 90 |
Est. completion date | September 2009 |
Est. primary completion date | April 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age over 18 years - Apart from benign non-toxic goiter no other serious illness - Signed proof of participation Exclusion Criteria: - Treatment with Levothyroxine - Former 131I-therapy - A thyroid volume above 100 ml or a retro-clavicular component - Unsafe contraception - Pregnancy or breastfeeding - Participation in another clinical trial - Previous allergic reaction toward rhTSH - Suspicion of malignancy in the thyroid gland either by clinical examination, laboratory findings (a raised serum calcitonin or ionized calcium)or by fine-needle aspiration biopsy - Physically or mental condition making it impossible to participate - Acute ischemic heart attach within the last 3 months - Alcohol and/or drug addicts |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | Odense University Hospital | Odense |
Lead Sponsor | Collaborator |
---|---|
Steen Bonnema |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | An intra-individual comparison of the thyroid 131I-uptake before and after stimulation with rhTSH /placebo | 24 and 96 hours after tracer administration | No | |
Primary | An inter-individual comparison of the thyroid 131I uptake between those who receive placebo and those who receive rhTSH | 24 and 96 hours after tracer administration | No | |
Primary | An estimation of which time-interval, injecting rhTSH, that is more favourable before 131I therapy (24 hours, 48 hours or 72 hours) | 24 and 96 hours after tracer administration | No | |
Primary | A comparison of the degree of goiter reduction when patients are prestimulated with rhTSH and receive a thyroid 131I dose of 50 Gy or when receiving conventional 131I, receiving a thyroid dose of 100 Gy | 3, 6, 9 and 12 months after 131I therapy | No | |
Secondary | A registration of adverse effects following rhTSH/placebo | All adverse effects occuring within one year follow-up | Yes | |
Secondary | Patient satisfaction (Visual Analogue Scale) before, 3 months post 131I therapy, and at the end of follow-up (1 year). | baseline, 3 and 12 months after 131I therapy | No | |
Secondary | Development of TPOab or TSHRab | At 12 months follow-up | Yes | |
Secondary | Thyroid function | At 12 months follow up. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06067594 -
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
|
||
Completed |
NCT01102127 -
Elastography in Thyroid Nodules
|
N/A | |
Completed |
NCT00615537 -
Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses
|
N/A | |
Recruiting |
NCT01761149 -
Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy
|
Phase 4 |